Insmed
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 912
- Market Cap
- $13.2B
- Introduction
Insmed, Inc. is a global biopharmaceutical company, which engages in the development and commercialization of therapies for patients with rare diseases. Its focuses on Brensocatib, and Treprostinil Palmitil Inhalation Powder (TPIP) pipeline. The company was founded in 1988 and is headquartered in Bridgewater, NJ.
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Arterial Hypertension
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-12-07
- Last Posted Date
- 2025-04-10
- Lead Sponsor
- Insmed Incorporated
- Target Recruit Count
- 102
- Registration Number
- NCT05147805
- Locations
- 🇺🇸
USA010, Winter Park, Florida, United States
🇺🇸USA017, New York, New York, United States
🇺🇸USA012, Denison, Texas, United States
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Brensocatib Tablets in Adults With Cystic Fibrosis
- First Posted Date
- 2021-10-25
- Last Posted Date
- 2023-11-01
- Lead Sponsor
- Insmed Incorporated
- Target Recruit Count
- 29
- Registration Number
- NCT05090904
- Locations
- 🇺🇸
USA001, Gainesville, Florida, United States
🇺🇸USA016, Augusta, Georgia, United States
🇺🇸USA025, Glenview, Illinois, United States
A Study of Treprostinil Palmitil Inhalation Powder (TPIP) In Pulmonary Arterial Hypertension (PAH)
- First Posted Date
- 2021-03-10
- Last Posted Date
- 2023-09-22
- Lead Sponsor
- Insmed Incorporated
- Target Recruit Count
- 1
- Registration Number
- NCT04791514
- Locations
- 🇺🇸
USA002, New York, New York, United States
Study to Evaluate ALIS (Amikacin Liposome Inhalation Suspension) in Participants With Nontuberculous Mycobacterial Lung Infection Caused by Mycobacterium Avium Complex
- Conditions
- Mycobacterium Infections, Nontuberculous
- Interventions
- First Posted Date
- 2020-12-21
- Last Posted Date
- 2025-06-26
- Lead Sponsor
- Insmed Incorporated
- Target Recruit Count
- 425
- Registration Number
- NCT04677569
- Locations
- 🇺🇸
USA008, Birmingham, Alabama, United States
🇺🇸USA062, Fresno, California, United States
🇺🇸USA060, Los Angeles, California, United States
Validation of Patient Reported Outcome Measures in Participants With Nontuberculous Mycobacterial Lung Infection Caused by Mycobacterium Avium Complex
- Conditions
- Mycobacterium Infections, Nontuberculous
- Interventions
- First Posted Date
- 2020-12-21
- Last Posted Date
- 2024-06-28
- Lead Sponsor
- Insmed Incorporated
- Target Recruit Count
- 99
- Registration Number
- NCT04677543
- Locations
- 🇺🇸
USA008, Birmingham, Alabama, United States
🇺🇸USA062, Fresno, California, United States
🇺🇸USA048, San Diego, California, United States
A Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib in Participants With Non-Cystic Fibrosis Bronchiectasis
- Conditions
- Non-Cystic Fibrosis Bronchiectasis
- Interventions
- First Posted Date
- 2020-10-20
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- Insmed Incorporated
- Target Recruit Count
- 1767
- Registration Number
- NCT04594369
- Locations
- 🇺🇸
USA013, Birmingham, Alabama, United States
🇺🇸USA080, Conway, Arkansas, United States
🇺🇸USA044, Little Rock, Arkansas, United States
Study of Dose Escalation of Liposomal Amikacin for Inhalation (ARIKAYCE™) - Extension Phase
- Conditions
- Cystic Fibrosis
- Interventions
- Drug: Arikayce™
- First Posted Date
- 2019-04-05
- Last Posted Date
- 2020-07-30
- Lead Sponsor
- Insmed Incorporated
- Target Recruit Count
- 49
- Registration Number
- NCT03905642
Assessment of INS1007 in Participants With Non-Cystic Fibrosis Bronchiectasis
- Conditions
- Non-Cystic Fibrosis Bronchiectasis
- Interventions
- First Posted Date
- 2017-07-17
- Last Posted Date
- 2023-03-27
- Lead Sponsor
- Insmed Incorporated
- Target Recruit Count
- 256
- Registration Number
- NCT03218917
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Phoenix Medical Group, Peoria, Arizona, United States
🇺🇸NewportNativeMD, Newport Beach, California, United States
Open-label Safety Extension Study Assessing Safety and Tolerability of LAI in Patients Who Participated in Study INS-212
- Conditions
- NTM Lung Infection Due to MAC
- Interventions
- Drug: LAI 590 mgDrug: Multi-drug regimen
- First Posted Date
- 2015-12-11
- Last Posted Date
- 2020-02-10
- Lead Sponsor
- Insmed Incorporated
- Target Recruit Count
- 163
- Registration Number
- NCT02628600
Study to Evaluate Efficacy of LAI When Added to Multi-drug Regimen Compared to Multi-drug Regimen Alone
- Conditions
- Mycobacterium Infections, Nontuberculous
- Interventions
- Drug: LAI (Liposomal Amikacin for Inhalation) 590 mg
- First Posted Date
- 2015-01-22
- Last Posted Date
- 2020-05-07
- Lead Sponsor
- Insmed Incorporated
- Target Recruit Count
- 336
- Registration Number
- NCT02344004